OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 107. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	1926
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	1002
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	954
ERK mediates interferon gamma-induced melanoma cell death	881
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance	741
The puppet master in the breast cancer “microecological community”: spatial and metabolic regulation of macrophage heterogeneity	721
SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers	621
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	583
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers	507
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	479
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	450
Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer	405
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	397
Immunotherapies in rare cancers	371
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	360
TGF-β signaling promotes cervical cancer metastasis via CDR1as	358
Mutation-specific dynamics of dedifferentiation trajectories and tumor–stromal interactions in thyroid cancer	324
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	307
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	303
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	302
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	295
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	280
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	280
Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer	268
Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance	266

circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	260
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	259
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	248
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	247
Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives	243
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	242
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	241
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	241
Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages	236
Biomarker-empowered precision navigation of CAR-T cell therapy	231
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia	230
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	225
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	223
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	221
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease	219
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	213
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	212
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	212
Context-dependent effect of glucocorticoid receptor activity shapes ovarian cancer cell plasticity and therapy response	206
LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target	202
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	202
Effects of RNA methylation on Tumor angiogenesis and cancer progression	201
Bidirectional role of neutrophils in tumor development	193
Emerging roles of tRNA-derived fragments in cancer	192
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	191
NK cells are never alone: crosstalk and communication in tumour microenvironments	191
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	190
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	189
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	185
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	183
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	182
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	179
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	179
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	178
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	174
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	174
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	173
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	173
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	172
Metabolic reprogramming and molecular crosstalk at the cancer–endothelial interface in ovarian carcinoma	170
Modeling pediatric low-grade glioma heterogeneity using human forebrain organoids	168
Correction: The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	164
Deconstructing cancer in 3D: models, mechanisms, and personalized solutions	164
Targeting cholesterol-driven immunometabolism in cancer: from molecular circuits to clinical translation	161
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis	158
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	158
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	158
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	157
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	157
Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation	154

lncRNAs: the unexpected link between protein synthesis and cancer adaptation	147
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	145
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	144
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	144
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	138
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	138
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	132
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	131
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	131
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	129
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	126
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	124
Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers	124
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	124
Context-dependent impact of type I interferon signaling in cancer	124
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	123
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	122
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	122
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	121
Molecular mechanisms of tumor resistance to radiotherapy	121
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	119
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	116
Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies	115
Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges	115
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	114
Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer	113
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	113
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	111
Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma	111
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age	109
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	109
Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the “Smart” exosome nanoparticle therapy	108
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives	107
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	107